Gregory M. McKee
Corporate Officer/Principal chez Young President Organization (Austin)
Profil
Gregory M.
McKee currently works at Young President Organization (Austin), as Member from 2006.
Mr. McKee also formerly worked at Nventa Biopharmaceuticals Corp., as President & Chief Executive Officer, Formulation Technologies LLC, as President & Chief Executive Officer, Akela Pharma, Inc., as President, CEO, Director & Head-Investor Relations in 2012, CONNECT, as President, Chief Executive Officer & Director from 2014 to 2019, Valentis, Inc., as Senior Director-Corporate Development from 2000 to 2003, Tryp Therapeutics, Inc., as Director in 2021, San Diego Regional Economic Development Corp., as Trustee, and GVIC Communications Corp., as President, Chief Executive & Financial Officer from 2003 to 2006.
Mr. McKee received his undergraduate degree from the University of Washington, graduate degree from the University of Pennsylvania, and Masters Business Admin degree from The Wharton School of the University of Pennsylvania.
Postes actifs de Gregory M. McKee
| Sociétés | Poste | Début |
|---|---|---|
| Young President Organization (Austin) | Corporate Officer/Principal | 01/01/2006 |
Anciens postes connus de Gregory M. McKee
| Sociétés | Poste | Fin |
|---|---|---|
| TRYPTAMINE THERAPEUTICS LIMITED | Directeur Général | - |
CONNECT
 CONNECT Miscellaneous Commercial ServicesCommercial Services CONNECT creates and scales companies in the technology and life sciences sectors. It creates an environment in which entrepreneurs and C-suite executives have access to the people, capital, and technology resources. The organization was founded in 1985 and is headquartered in San Diego, CA. | Directeur Général | 01/02/2019 |
Akela Pharma, Inc.
 Akela Pharma, Inc. Pharmaceuticals: MajorHealth Technology Akela Pharma, Inc. operates as a drug development company, which develops and manufactures pharmaceutical formulations and drugs. The company operates as a specialty contract pharmaceutical formulation developer and clinical and commercial drug manufacturer for proprietary drug products through its wholly-owned subsidiary, PharmaForm LLC, a pharmaceutical intellectual property development company. It provides specialty contract services in the area of pharmaceutical dosage form development, preclinical, scale-up, clinical and commercial supply manufacturing, focusing on controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying and liquid filled capsules. Akela Pharma was founded on November 15, 1988 and is headquartered in Austin, TX. | Directeur Financier/CFO | 09/09/2010 |
| GVIC COMMUNICATIONS CORP. | Directeur Financier/CFO | 23/03/2006 |
Valentis, Inc.
 Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Corporate Officer/Principal | 01/06/2003 |
Formation de Gregory M. McKee
| University of Washington | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| University of Pennsylvania | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
GVIC Communications Corp.
 GVIC Communications Corp. Publishing: NewspapersConsumer Services GVIC Communications Corp. operates as an information and marketing solutions company. The firm engages in the provision of information and related services through print and digital media. It operates through following segments: Environmental and Property Information, Commodity Information and Community Media. The company was founded in 1990 and is headquartered in Vancouver, Canada. | Consumer Services |
Akela Pharma, Inc.
Akela Pharma, Inc. Pharmaceuticals: MajorHealth Technology Akela Pharma, Inc. operates as a drug development company, which develops and manufactures pharmaceutical formulations and drugs. The company operates as a specialty contract pharmaceutical formulation developer and clinical and commercial drug manufacturer for proprietary drug products through its wholly-owned subsidiary, PharmaForm LLC, a pharmaceutical intellectual property development company. It provides specialty contract services in the area of pharmaceutical dosage form development, preclinical, scale-up, clinical and commercial supply manufacturing, focusing on controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying and liquid filled capsules. Akela Pharma was founded on November 15, 1988 and is headquartered in Austin, TX. | Health Technology |
Formulation Technologies LLC
 Formulation Technologies LLC Medical/Nursing ServicesHealth Services Formulation Technologies LLC operates as a contract manufacturer in the areas of pharmaceutical dosage form development. It specializes in controlled release and bioavailability enhancement technologies, such as hot melt extrusion, fluid bed processing, liquid filled capsules, and spray drying. The company was founded by Robert O. Williams III and is headquartered in Austin, TX. | Health Services |
Nventa Biopharmaceuticals Corp.
 Nventa Biopharmaceuticals Corp. Medical SpecialtiesHealth Technology Nventa Biopharmaceuticals Corp. discovered, developed and commercialized stress protein-based therapeutic vaccines. The company was headquartered in Victoria, Canada. | Health Technology |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
CONNECT
CONNECT Miscellaneous Commercial ServicesCommercial Services CONNECT creates and scales companies in the technology and life sciences sectors. It creates an environment in which entrepreneurs and C-suite executives have access to the people, capital, and technology resources. The organization was founded in 1985 and is headquartered in San Diego, CA. | Commercial Services |
San Diego Regional Economic Development Corp.
 San Diego Regional Economic Development Corp. Miscellaneous Commercial ServicesCommercial Services San Diego Regional Economic Development Corp. operates as a non-profit organization. It mobilizes business, government, and civic leaders to maximize the region’s economic prosperity and global competitiveness. The company is headquartered in San Diego, CA. | Commercial Services |
Tryp Therapeutics, Inc.
 Tryp Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tryp Therapeutics, Inc. is a pharmaceutical company, which engages in identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. The company was founded on September 24, 2019 and is headquartered in Kelowna, Canada. | Health Technology |
| Young President Organization (Austin) |